Sjogren's Syndrome: An Update on Diagnosis and ManagementMedscapeTolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-920. Abstract Seror R, Sordet C, Guillevin L, et al. Tolera…
Biogen Idec presenta sus prioridades estratégicas para 2012 en el 30º Congreso …ecodiarioSeguir avanzando el programa de Fase 3 de daclizumab sobre EM. La creación de equipos científicos de tipo mundial en sus áreas terapéuticas principales. Av…
Biogen Idec presenta sus prioridades estratégicas para 2012 en el 30º Congreso …elEconomista.esSeguir avanzando el programa de Fase 3 de daclizumab sobre EM. La creación de equipos científicos de tipo mundial en sus áreas terapéuticas principal…
Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan …Business Wire (press release)Continuing to advance the daclizumab Phase 3 program in MS. Building world-class scientific teams in its core therapeutic areas. Advancing the com…
Biogen Idec stellt auf der 30. Annual J.P. Morgan Healthcare Conference …Business Wire (Pressemitteilung)Weitere Fortentwicklung des Programms Phase 3 mit Daclizumab bei MS. Bildung von Wissenschaftlerteams von Weltklasse in den therapeutischen Kernb…
Biogen Idec presenta le priorità strategiche per il 2012 in occasione della …Business Wire (Comunicati Stampa)… lancio ea richieste normative successivi. realizzazione del programma di fase 3 per il daclizumab nella SM. approfondimento delle colla…
This Month in Archives of NeurologyArchives of NeurologyGorman et al (SEE ARTICLE) report the use of daclizumab in pediatric-onset multiple sclerosis (POMS). They find that daclizumab may be a safe and at least partially effective treatment option for …
MS, virus link shown in new findingseMaxHealthThe research means there may be ways to halt the progression of multiple sclerosis with anti-viral drugs or Rituximab, a drug that kills immune cells that harbor the virus. The study also found a possible l…
Biogen Idec présente ses priorités stratégiques pour 2012 lors de la 30ème …TF1… qui auront tous deux des données publiées cette année. poursuivant le développement du programme de phase 3 du daclizumab pour la SP. renforçant les collabora…
Biogen Idec presenta le priorità strategiche per il 2012 in occasione della …ANSA.it… lancio ea richieste normative successivi. realizzazione del programma di fase 3 per il daclizumab nella SM. approfondimento delle collaborazioni strategiche esis…